Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study

Cladribine is currently registered as a 10-milligram tablet formulation with a fixed cumulative dosage of 3.5 mg/kg over 2 years. It is important to investigate if an increased dosage may lead to further clinical stability with preserved safety. This study used an off-label subcutaneous (s.c.) formu...

Full description

Bibliographic Details
Main Authors: Konrad Rejdak, Adriana Zasybska, Aleksandra Pietruczuk, Dariusz Baranowski, Sebastian Szklener, Magda Kaczmarek, Zbigniew Stelmasiak
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Journal of Clinical Medicine
Subjects:
subcutaneous cladribine
relapsing multiple sclerosis
long-term efficacy
safety
Online Access:https://www.mdpi.com/2077-0383/10/21/5207

Internet

https://www.mdpi.com/2077-0383/10/21/5207

Similar Items